Logo Image
News
Watch
Expert ConversationsShows & PodcastsNews & Analysis
Conferences
Conference CoverageConference Listing
CME/CE
More
Partners
Publications
NeurologyLiveBridging the GapsInternational Journal of MS Care
Resources
Expert AuthorsFDA NewsFeaturesFuture Leaders in NeurologyGiants of Multiple SclerosisInteractive ToolsJob BoardLive EventsNeurology ResourcesParkinsonism Practical GuideSponsoredThe G.L.O.B.Virtual Events

Subscribe

  • News
  • Watch
  • Conferences
  • CME/CE
  • Partners
  • Publications
  • Resources
  • Subscribe
  • Dementia and Alzheimer Disease
  • Epilepsy
  • Genetic Disorders
  • Headache and Migraine
    • Migraine
  • MS and Demyelinating Disorders
    • NMOSD
    • Multiple Sclerosis
  • Movement Disorders
    • Parkinson Disease
    • Dyskinesia
    • Huntington Disease
  • Neuro-Oncology
  • Neuromuscular
    • Chronic Inflammatory Demyelinating Polyneuropathy
    • Muscular Dystrophy
    • Ataxia
    • Generalized Myasthenia Gravis
    • LEMS
  • Rare Diseases
  • Sleep Disorders
    • Narcolepsy
    • Excessive Daytime Sleepiness
    • Insomnia
  • Stroke
Spotlight -
Expert Authors|
FDA News|
Upcoming Live Events|
AANEM 2026|
ECTRIMS 2026|
CNS 2026|
WSC 2026|
Parkinsonism Practical Guide
Advertisement

William Pass, DVM

Advertisement

Articles by William Pass, DVM

Exploring CB1, CB2 in Various Neurological Conditions

ByWilliam Pass, DVM
October 17th 2018

Cannabinoids are being explored in a variety of conditions, ranging from Alzheimer disease to migraine.

Advertisement

Latest Updated Articles

  • Exploring CB1, CB2 in Various Neurological Conditions
    Exploring CB1, CB2 in Various Neurological Conditions

    October 17th 2018



Advertisement
Advertisement

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

1

FDA Approves Cemdisiran as New Treatment for Generalized Myasthenia Gravis

2

Levetiracetam Misses Primary Endpoint in Early Alzheimer Trial

3

FDA Approves Venglustat as First Therapy for Neurological Manifestations of Type 3 Gaucher Disease

4

Phase 2 SPINOZA Trial to Test CETP Inhibitor Obicetrapib in APOE-Stratified Preclinical Alzheimer Disease

5

Perfuze Receives FDA Clearance for NeuroSheath 8F Long Sheath

  • About Us
  • Advisory Board
  • Editorial
  • Contact Us
  • Advertise
  • Contact MJH LS
  • Do Not Sell My Information
  • Terms and Conditions
  • Privacy
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

  • Contagion Live
  • CGT Live
  • Neurology Live
  • HCP Live
  • Oncology Live
  • Contemporary Pediatrics
  • Contemporary OBGYN
  • Urology Times
  • The Educated Patient
  • Patient Care Online
HCP Live Network
Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us